Inject one day early before your trip, then take your next dose up to two days late after you return (semaglutide) or up to four days late (tirzepatide missed dose window)
Patients using GLP-1 medications should maintain contact with their Hers provider and a primary care physician to coordinate care, report persistent side effects, and address any signs of dehydration, acute abdominal pain, or thyroid symptoms
GLP-1 RA use in complicated diabetes: There is no clear evidence regarding the use of GLP-1 RA in acute myocardial infarction, although the use of these agents is encouraged in patients with asymptomatic and stable coronary artery disease (CAD)
Talk with a medical weight management specialist to help determine the right approach for you one that is safe, sustainable and evidence-based
Potential Cardiovascular Benefits Current studies are exploring how it may reduce heart risks, especially in patients with obesity and diabetes
Current Options While Waiting for Retatrutide As exciting as Retatrutide's potential may be, it is still in clinical trials, and Retatrutide clinical trials continue to evaluate its efficacy and safety